A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies

Prashar, Paritosh; Swain, Sonali; Adhikari, Nisha; Aryan, Punit; Singh, Anupama; Kwatra, Mohit; Prabhakar, Bellur S.

doi:10.1016/j.antiviral.2022.105349

Cited by 6 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, the second method involves the acquisition of polyvalent nanobodies through engineering in genetics and screening in phage display, utilising camels or other transgenic animals as sources. 109…”

Section: Monoclonal Antibodies Therapymentioning

confidence: 99%

SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges

Liu

Liang

Cheng

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

The COVID‐19 pandemic represents an unparalleled global public health crisis. Despite concerted research endeavours, the repertoire of effective treatment options remains limited. However, neutralising‐antibody‐based therapies hold promise across an array of practices, encompassing the prophylaxis and management of acute infectious diseases. Presently, numerous investigations into COVID‐19‐neutralising antibodies are underway around the world, with some studies reaching clinical application stages. The advent of COVID‐19‐neutralising antibodies signifies the dawn of an innovative and promising strategy for treatment against SARS‐CoV‐2 variants. Comprehensively, our objective is to amalgamate contemporary understanding concerning antibodies targeting various regions, including receptor‐binding domain (RBD), non‐RBD, host cell targets, and cross‐neutralising antibodies. Furthermore, we critically examine the prevailing scientific literature supporting neutralising antibody‐based interventions, and also delve into the functional evaluation of antibodies, with a particular focus on in vitro (vivo) assays. Lastly, we identify and consider several pertinent challenges inherent to the realm of COVID‐19‐neutralising antibody‐based treatments, offering insights into potential future directions for research and development.

show abstract

Section: Monoclonal Antibodies Therapymentioning

confidence: 99%

SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges

Liu

Liang

Cheng

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…B-cells can be isolated from transgenic animals (encoding human antibodies) or convalescent humans to isolate target-specific antibodies. Single B-cell technology has seen tremendous advancement in the past decade and is beneficial in many important applications including screening repertoires for neutralizing antibodies that can be employed treatment of infectious diseases [42], studying immune response after vaccination [43], etc. Antibody discovery is also aided by computational strategies, which allow the analysis of the immunogenicity profile, biophysical properties, and developability profile of lead antibody molecules for better chances of success during clinical trials [26].…”

Section: Strategies For Human Mab Discoverymentioning

confidence: 99%

Leveraging monoclonal antibodies as therapeutics to address antimicrobial resistance in bacteria

Verma¹

2022

J App Biol Biotech

View full text Add to dashboard Cite

Over the past two decades, several technologies have become available to rapidly develop therapeutic monoclonal antibodies (MAbs) against any target of interest. Consequently, antibodies have emerged as key biologics for the treatment of various forms of cancer, autoimmune diseases, and infectious diseases. Antimicrobial resistance (AMR) is a condition, wherein the microbes evolve and stop responding to the available treatment options. The development of AMR makes it harder to treat infections resulting in increased severity of disease, deaths, and risk of infection spread. Driven by the misuse of antibiotics, globally, there has been a consistent spread of multi-and pan-resistant bacteria that are untreatable with the existing antibiotics. Unfortunately, the emergence of AMR bacteria outpaces the rate at which new antibiotics are being discovered. Therefore, due to the ever-increasing burden of AMR, there is an unmet need for next-generation strategies to combat infections. With the approval of several MAbs for treatment of various conditions and three MAbs for the treatment of bacterial infections, they are currently being explored as a therapeutic alternative for the treatment of AMR bacteria. It is envisaged that antibody-based drugs can be administered as a standalone therapy or as an adjunct therapy in combination with antibiotics for improved efficacy and hold promise to address the problem of AMR. This review describes the strategies employed for the development of antibody-based drugs and discusses the MAbs that are already approved as therapeutics or are at various stages of the drug development pipeline for the treatment of bacterial infections.

show abstract

“…Single-cell analysis is of great scientific importance [1][2][3][4][5] and has a good potential for clinical practices [6][7][8][9] and industrial applications. 10,11 Recently, droplet-based microfluidics became a popular tool for constructing single-cell assays. By compartmentalizing each cell into a pico-liter size droplet, up-concentrated and well-confined reactions can be performed, allowing single-cell analysis at all levels of the central dogma of molecular biology (including genomic, transcriptomic, proteomic, and metabolomic) in a massively parallel manner at a low cost.…”

Section: Introductionmentioning

confidence: 99%

High precision, high throughput generation of droplets containing single cells

et al. 2022

View full text Add to dashboard Cite

show abstract

A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies

Cited by 6 publications

References 28 publications

SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges

SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges

Leveraging monoclonal antibodies as therapeutics to address antimicrobial resistance in bacteria

High precision, high throughput generation of droplets containing single cells

Contact Info

Product

Resources

About